GBA1 and early-onset autosomal dominant Alzheimer disease: There were no differences between the groups in CSF biomarkers of Alzheimer’s disease pathology, except for higher levels of phosphorylated tau181 in controls compared to asymptomatic GBA1 carriers (Table 1).